Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar. Closed at $2.00, 58% below $4.73, its close on the day of its Oct 9 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$2.6MCash on Hand
2.2mo Cash Runway
4.2%Short Interest
Follow BIAF by emailGet an email when BIAF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BIAF, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
bioAffinity reported a record 235 CyPath Lung tests in October 2026, up 29% from October 2025, equal to about 45% of Q3 2026 test volume. The company cited an expanded sales team and R&D work on asthma and COPD. Form 8-K · SEC filing · Press release
Nov 6, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 6, 2026 ·
Earnings Reported Q3 2026 results: revenue about $1.1 million versus $1.4 million a year earlier, net loss about $5.3 million versus $5.1 million, and cash of about $2.6 million at September 30, 2026. CyPath Lung test unit sales doubled year to date and testing revenue rose 79% for the first nine months. Form 8-K · SEC filing · Press release
Nov 3, 2026 ·
Financing bioAffinity Technologies filed to correct a typo in its at-the-market offering amount, which the filing says is $5,228,226 of common stock sold through WallachBeth Capital LLC. Shares last traded at $2.91 on October 30, 2026. Form 424B5 · SEC filing
Nov 2, 2026 ·
Financing bioAffinity Technologies is raising up to an additional $3,428,226 of common stock through WallachBeth Capital LLC under an at-the-market sales agreement, on top of $1,300,000 already sold. Last reported price was $2.91 per share on October 30, 2026. Form 424B5 · SEC filing
Oct 29, 2026 ·
bioAffinity Technologies will join the Lung Cancer Initiative of North Carolina's Battle of the Blues event on November 5, 2026, to promote awareness of its noninvasive CyPath Lung test. The filing contains no new trial data, financing or regulatory news. Form 8-K · SEC filing · Press release
Oct 23, 2026 ·
Shareholder vote Stockholders of bioAffinity Technologies will vote at a November 20, 2026 special meeting on issuing up to 1,128,272 shares for August 2026 warrants and 980,072 shares for October 2026 warrants, plus a non-public offering authorization, cutting authorized shares from 350,000,000 to 200,000,000, and adjournment. Form DEF 14A · SEC filing
Oct 15, 2026 ·
bioAffinity Technologies will sponsor a Learning Theater presentation at CHEST 2026 on Oct 21, 2026, on CyPath Lung use in lung cancer risk stratification, with preliminary data from its investigational asthma and COPD test. Its Medical and Scientific Advisory Board will also meet at the conference. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2029 · N/A · Recruiting · Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in… Registry primary completion date, not a results date
Dec 2025 · N/A · Recruiting · Collection of Sputum and Labeling for Lung Cancer Registry date passed, readout not confirmed
💰 Cash Runway & Dilution Risk
BIAF holds $2.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $3.5M/quarter from operations,
an estimated runway of 2.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:60 · High
Cash runway 2 months +40
ATM program on file since Nov 2026 +15
Going-concern doubt in the latest 10-Q +15Based on the Company’s current expected level of operating expenditures and the cash and cash equivalents on hand at September 30, 2026, management concludes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve (12) months subsequent to the issuance…10-Q, Nov 2026
Raised after last reported balance sheet (Oct 2026) -10
Share count 1,820,006 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full BIAF picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIAF and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.